Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria in Liberia, 2022-2023.

ABSTRACT:

Background

Artemether-lumefantrine (AL) is currently the first-line treatment for uncomplicated Plasmodium falciparum malaria in Liberia. To ensure antimalarial treatments are effective, the World Health Organization (WHO) recommends routinely testing the efficacy of oral artemisinin-based combination therapy (ACT) for uncomplicated malaria using therapeutic efficacy studies (TES) every two years. The most recent TES in Liberia conducted from December 2017 to May 2018 reported a PCR-corrected adequate clinical and parasitological response (ACPR) of 90.2% in Bensonville and 92.7% in Saclepea for artesunate-amodiaquine (ASAQ), and 100% in Kakata and Sinje for AL. Due to these findings AL was prioritized over ASAQ as the first-line ACT in Liberia. However, ASAQ is commonly available i

SUBMITTER: Koko VS 

PROVIDER: S-EPMC12502184 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature